Kevin W. Christensen

Kevin W. Christensen, PhD is a director in BRG’s Washington, DC office. Dr. Christensen specializes in antitrust and competition policy, damages analysis, and public policy, which he often applies in the context of the pharmaceutical industry.

He regularly works on class action litigation matters to address questions of class certification and estimation of classwide damages. He has submitted expert reports to the US District Court for the District of Columbia, US District Court for the Eastern District of Virginia, state courts, and regulatory agencies. Dr. Christensen has provided deposition testimony in state and federal courts. Additionally, he has written white papers submitted to the State of Florida’s Department of Transportation and drafted portions of new product applications submitted to the US Food and Drug Administration (FDA).

Dr. Christensen has been involved in competition and antitrust matters that included price fixing, monopoly and attempted monopoly, monopsony and attempted monopsony, market allocation, raising rivals costs, and tying and bundling allegations. He also has worked on several mergers and acquisitions and nonpublic investigations by federal agencies, estimated economic damages in antitrust and false advertising litigations, and provided testimony on economic damages resulting from bribery. His disputes and investigations work spans industries including oil and gas, pharmaceutical, biotechnology, medical device, banking, automobile finance, wholesale distribution, transportation, consumer packaged goods (CPG), agriculture, building materials, tourism, and gaming.